Author

N. S. Persky

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:genetic perturbation / CRISPR· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

D. E. Root· 3 shared A. L. Hillis· 1 shared A. Raimondi· 1 shared A. Toker· 1 shared B. A. Leeper· 1 shared B. Adane· 1 shared B. Walter· 1 shared C. A. French· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. E. Root

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cholesterol biosynthesis inhibition synergizes with AKT inhibitors in triple-negative breast cancer

A. Toker, A. L. Hillis, T. D. Martin, H. E. Manchester, J. M. Hogstrom, N. Zhang, E. Lecky, N. Kozlova, N. S. Persky, D. E. Root, M. Brown, K. Cichowski, S. J. Elledge, T. Muranen, D. A. Fruman, , R. R. Madsen

This study identifies a synergistic effect between AKT inhibitors and pitavastatin in killing triple-negative breast cancer cells by targeting cholesterol trafficking.

bioRxiv · Jan 16, 2024 · PreprintCancer Biology

EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes

Y. Huang, R. T. Durall, N. M. Luong, H. J. Hertzler, J. Huang, P. C. Gokhale, B. A. Leeper, N. S. Persky, D. E. Root, P. V. Anekal, P. D. Montero Llopis, C. N. David, J. L. Kutok, A. Raimondi, K. Saluja, , C. A. French

This study identifies EZH2 as a dependency in NUT carcinoma, showing that combining EZH2 and BET inhibitors synergistically blocks tumor growth and prolongs survival.

bioRxiv · Aug 15, 2023Cancer Biology

Genome-wide CRISPR and small-molecule screens uncover targetable dependencies in ATRT

D. J. Merk, S. Hirsch, F. Tsiami, B. Walter, L. A. Haeusser, S. Babaei, J. Admar, N. Casadei, C. Roggia, M. Spohn, J. Schittenhelm, S. Singer, U. Schueller, F. Piccioni, N. S. Persky, , G. Tabatabai

This study identifies targetable genetic dependencies in ATRT using CRISPR and small-molecule screens, revealing CDK4/6 inhibitors as potent therapeutic options.

bioRxiv · Dec 9, 2020 · PreprintCancer Biology